Pharma Mar SA · BME:PHM

Pharma Mar SA — Investor Presentation (November 2015)

41 slides from Pharma Mar SA's investor presentation, November 2015

  1. Slide 1: Corporate Presentation 2015

    CORPORATE PRESENTATION 2015

  2. Slide 2: Disclaimer

    DISCLAIMER This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are "forward-looking statements" and are based on Management’s current expectations. Factors that could cause future results to dif

  3. Slide 3: Corporate Overview

    CORPORATE OVERVIEW BIOTECH ONCOLOGY COMPANY  Leader in developing and commercializing marine-derived oncology drugs.  Unique R&D capability to bring first in class molecules to the pipeline.  Profitable company with growing revenues and EBITDA. GLOBAL COMMERCIAL PRESENCE WITH A PRODUCT IN THE MAR

  4. Slide 4: Fully Integrated: Drug Development Capabilities

    FULLY INTEGRATED: Drug Development Capabilities FROM MARINE EXPEDITIONS TO COMMERCIALIZATION  Marine-derived products  Clinical Trials  New drug candidates  Production  Molecule optimization  Licensing  Build a library (165,000 samples)  Commercialization 4

  5. Slide 5: Yondelis: First Antitumoral Compound of Marine Origin

    Yondelis®: First Antitumoral Compound of Marine Origin MARKETED IN MORE THAN 80 COUNTRIES FOR:  The treatment of advanced or metastatic soft tissue sarcoma and  Relapsed platinum-sensitive ovarian cancer in combination with DOXIL®/Caelyx®. LICENSED TO JANSSEN IN THE US & ROW  YONDELIS® receives m

  6. Slide 6: Yondelis: Proof of Concept

    Yondelis®: Proof of Concept CLINICAL PROGRAM / PHASE REGISTRATION INDICATION PHASE I PHASE II III APPLICATION MARKET PARTNERS Yondelis® Soft Tissue Sarcoma 2nd/3rd line; Single agent Marketed 2007 EU/others R/R ovarian cancer 2nd/3rd line; (Yondelis®+Doxil) Marketed 2009 EU/others Soft Tissue Sarcom

  7. Slide 7: Market Potential Unlocked Through Regional Specialists

    MARKET POTENTIAL UNLOCKED Through Regional Specialists EU MARKET: ~ 31% WORLD ONCOLOGY MARKET PHARMAMAR SUBSIDIARIES SCANDINAVIA & EASTERN EUROPE : Sales force: Swedish Orphan Biovitrum GREECE, CYPRUS AND BALKAN COUNTRIES : Sales force: Genesis Pharma 7

  8. Slide 8: Yondelis: Commercial Success

    Yondelis®: Commercial Success Validates Marine Biotechnology Platform Yondelis® is approved in more than 80 countries for advanced STS and, in combination with Doxil / Caelyx, for relapsed platinum-sensitive ovarian cancer. Yondelis® is partnered with Janssen and TAIHO Pharmaceuticals. US : APPROVED

  9. Slide 9: PM1183: Potent Oncology Compound

    PM1183: Potent Oncology Compound PM1183, a second generation Yondelis®, with activity in new indications. Yondelis® PM1183 Me O HO O CH3 OPTIMIZATION NH MeO IMPROVED PK PROFILE NH OCH3 N O HO H O HO AcO S AcO S O H H O N N N N O O O O OH OH 9

  10. Slide 10: PM1183: Main Features of MoA

    PM1183: Main Features of MoA Blockade of trans-activated transcription but not of basal transcription. Induction of the degradation of RNA Pol II but not of RNA Pol I nor of RNA Pol III. RNA POL II BLOCKADE RNA POL II DEGRADATION P P CDK7 CDK9 RNAPII P P P PM1183 P PM1183 PROTEASOME DNA RNAPII RNAPI

  11. Slide 11: PM1183: Marked Effect on Tumor Microenvironment

    PM1183: MARKED EFFECT ON TUMOR MICROENVIRONMENT by inhibiting transcription of selected cytokines Marked effect on tumor microenvironment by inhibiting transcription of selected cytokines (VEGF, CCL2, IL6, IL8, PTX3) in Tumor-Associeated Macrophages. PM1183 TUMOR-ASSOCIATED MACROPHAGES INHIBITION OF

  12. Slide 12: PM1183: Favourable PK Profile vs. Yondelis

    PM1183: Favourable PK Profile vs. Yondelis® PM1183, 4 mg/m2  PM1183 is administered as a 1h infusion Yondelis, 1 mg/m2 versus 24h infusion with Yondelis®.  PM1183 is well-tolerated with peripheral administration, while Yondelis® is administered via central catheter. PM1183® VS. Yondelis® AUC HL 

  13. Slide 13: PM1183: Fast-to-Market Development Strategy

    PM1183: Fast-to-Market Development Strategy CLINICAL PROGRAM / INDICATION PHASE I PHASE II PHASE III REGIST. MARKET PARTNERS PM1183 Plat. Resistant ovarian cancer 2nd/3rd line Single agent SCLC 2nd/3rd line 1183 + Doxorrubicin BRCA 1/2 breast cancer 2nd/3rd line Single agent Combination Studies 13

  14. Slide 14: PM1183 Phase II Resistant Ovarian Cancer

    PM1183 PHASE II RESISTANT OC: 1.0 PM01183 (N=17 C=4) 0.9 Topotecan (N=16 C=2) PFS Censored Cumulative probability 0.8 0.7 HR: 0.30 (95%CI 0.12-0.72) 5.7 mo. 0.6 p=0.005*  Superior PFS 0.5 0.4 1.7 mo. 0.3 0.2 0.1 0.0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 1.0 PM01183 (N=17 C=9) Topotecan (N=16 C=4

  15. Slide 15: Phase III in Platinum-Resistant Ovarian Cancer

    PM1183: Phase III in Platinum-Resistant Ovarian Cancer TRIAL DESIGN Arm A: 420 Patients PM1183 (D1 q3wk i.v.) 3.2 mg/m2 RANDOMIZATION 1:1 No Crossover Allowed • ECOG PS (0 vs. ≥ 1) Arm B: Stratified by: • PFI (1-3 vs. > 3 months) PLD (D1 q4wk i.v.) • Prior CT (1-2 vs. 3 lines) or Topotecan (D1-D5 q3

  16. Slide 16: PM1183 with Doxo in SCLC

    PM1183: PM1183 with Doxo: Active Treatment as Second-line Therapy in SCLC Best RECIST v.1.1 overall response during treatment (n=21). CR 10% SD PR 14% 57% PD 19% CI, confidence interval; CR, complete response; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable dise

  17. Slide 17: PM1183 with Doxo in SCLC: Response by CTFI

    PM1183: PM1183 with Doxo: Active Treatment as Second-line Therapy in SCLC Best RECIST v.1.1 response according to CTFI. N 12 10 18% 8 30% CR PR 6 30% ORR 100% SD 4 82% 95%CI: PD 71-100% 2 40% 0 CTFI ≤90 days = Resistant (R) (n=10) CTFI>90 days = Sensitive (S) (n=11) CI, confidence interval; CR, comp

  18. Slide 18: PM1183 with Doxo in SCLC: Waterfall Plot

    PM1183: PM1183 with Doxo: Active Treatment as Second-line Therapy in SCLC Waterfall plot showing maximal tumor variation in size according to CTFI (n=21). 100 Increase (%) 90 80 70 Sensitive=S Resistant=R 60 50 40 30 20 PD 10 0 10 20 30 PR Decrease 40 50 60 70 80 90 90.5% 9.5% 100 CTFI, chemotherapy

  19. Slide 19: PM1183 with Doxo in SCLC: Kaplan-Meier PFS

    PM1183: PM1183 with Doxo: Active Treatment as Second-line Therapy in SCLC Kaplan-Meier global PFS and according to CTFI (n=21). 1.0 Cumulative probability 0.9 0.8 0.7 0.6 PFS: 4.6 months (95%CI: 3.3-8.0 0.5 months) 0.4 0.3 0.2 0.1 0.0 0 1 2 3 4 5 6 7 8 9 10 11 12 Time (months) Global (N=21 C=3) CI,

  20. Slide 20: Aplidin: Marine Compound

    Aplidin®: Marine Compound Aplidium albicans PLITIDEPSIN Isolated from the marine tunicate Aplidium albicans. “First in class” drug with a new and different mechanism of action compared to current drugs used in the clinic. Orphan drug status in multiple myeloma. 20

  21. Slide 21: Aplidin: Targets eEF1A2

    Aplidin®: Targets eEF1A2 Aplidin® TARGETS eEF1A2 NON-CANONICAL FUNCTIONS OF eEF1A2 Proto-oncogene over-expressed in different tumor types (e.g. Multiple eEF1A2 myeloma). Reorganization of the actin cytoskeleton. Favors cell migration and invasion. Regulation of oxidative stress. Inhibition of apopto

  22. Slide 22: Aplidin: Pipeline

    Aplidin®: Pipeline CLINICAL PROGRAM / INDICATION PHASE I PHASE II PHASE III REGIST. MARKET * PARTNERS Aplidin® R/R multiple myeloma 4th line; Aplidin® + Dexameth EU/others R/R T-cell lymphoma (Pivotal) Single agent R/R multiple myeloma Aplidin® + Bortezom +Dexamethasone * Others partners: Specialise

  23. Slide 23: Aplidin: ADMYRE (Phase III)

    Aplidin®: ADMYRE (Phase III) Relapsed/Refractory Multiple Myeloma  Design: Phase III, randomized (2:1), multicentre, after 3 but no more than 6 lines of chemotherapy, 2-parallel group.  Objective: Progression-Free Survival (PFS).  Primary Endpoint: Increase of 60% in PFS in Arm A.  Number of pat

  24. Slide 24: Pipeline

    Pipeline: Registration Clinical Program / Indication Phase I Phase II Phase III Application Market Partners Yondelis® Soft Tissue Sarcoma 2nd/3rd line; EU/others Single agent R/R ovarian cancer 2nd/3rd line; EU/others (Yondelis®+Doxil) Soft Tissue Sarcoma 2nd/3rd line; US Single agent R/R ovarian ca

  25. Slide 25: Zeltia Group Financial Profile: Increasing Total Revenues

    ZELTIA GROUP FINANCIAL PROFILE: Increasing Total Revenues Caelyx® Shortage in EU: 3Q 2011 2Q 2013 178 178 180 161 161 164 160 25,9 28,4 7,7 22,8 Total revenues (Euro million) 23,5 140 120 79,4 80,6 72,4 79,1 82,3 100 OTHER INCOME 80 BIOPHARMACEUTICAL 60 CONSUMER CHEMICALS 40 73,2 71,2 64,7 61,8 66,5

  26. Slide 26: Driving Profitability Through Revenue Diversification

    DRIVING PROFITABILITY Through Revenue Diversification +25,7 +23,8 35,0 +20,4 5,7 30,0 3,8 +13,2 4,9 25,0 NET EBITDA (Euro million) 20,0 8,5 15,0 28,9 26,2 22,8 BIOTECHNOLOGY 10,0 CONSUMER CHEMICALS 13,1 5,0 10,0 OTHER 0,0 -8,0 -7,3 -6,3 -8,4 -8,9 -5,0 -10,0 -5,9 -15,0 -3,9 2010 2011 2012 2013 2014 2

  27. Slide 27: Deleveraging through Improved Operating Cash Flow

    DELEVERAGING through Improved Operating Cash Flow In FY2014, Zeltia reduced group net debt by 15% and had a positive operating cash flow. GROUP NET DEBT OPERATING CASH FLOW Euro million Euro million 90 86 79 80 22,1 20,7 65 20 70 CASH FLOW NET DEBT 60 55 9,7 10 50 DEC-11 40 0 DEC-13 DEC-14 DEC-12 30

  28. Slide 28: Upcoming Key Events

    UPCOMING KEY EVENTS ESGO  Nice, (France), October 24 - 27, 2015 AACR-NCI-EORTC:  Boston, November 5-9, 2015. CTOS 2015: “CONNECTIVE TISSUE ONCOLOGY SOCIETY ANNUAL MEETING”  Salt Lake City, November 4-7, 2015 ASH 2015: “AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING”  Orlando, December 5-8, 2015 2

  29. Slide 29: Appendix

    APPENDIX

  30. Slide 30: Other Businesses

    OTHER BUSINESSES RNAI TECHNOLOGY Clinical Development Preclinical Development Phase I Phase II Phase III Focused on the research and development of new SYL040012 Glaucoma Phase IIb treatments based on RNA interference (RNAi) gene SYL1001 Ocular Pain silencing technology. DIAGNOSTICS DNA analysis tec

  31. Slide 31: Key Facts and Current Shareholders

    KEY FACTS and Current Shareholders KEY FACTS Ticker: ZEL SM Market Cap*: € 931 million 2014 Total Income: € 178 million 2014 EBITDA: € 25,7 million * As of 22sd Oct. 2015 Fernández Family 24,0% Free float 63,7% Kutxabank 2,0% Rosp Coruna Particip.5,0% Other board members and Norges Bank employees 2,

  32. Slide 32: Yondelis: Targeting Unmet Medical Needs

    Yondelis® Targeting Unmet Medical Needs SOFT TISSUE SARCOMA (STS) OVARIAN CANCER  Uncommon sarcoma developing in  4% of all female cancers in the US. connective tissue.  Ranks 5th in terms of total cancer  4 new cases of STS are detected per deaths annually. 100,000 people, accounts for 2% of 

  33. Slide 33: Yondelis STS-201: Pivotal Phase II STS Data

    Yondelis® STS-201: Pivotal Phase II STS Data Significant prolongation in time to progression and progression-free survival in a poor-prognosis patient population, providing basis for approval by the European Commission in 2007. CLINICAL TRIAL DESIGN  270 patient (260 treated), randomized, multicent

  34. Slide 34: Yondelis OVA-301: Pivotal Phase III Ovarian Cancer Data

    Yondelis® OVA-301: Pivotal Phase III Ovarian Cancer Data Improved progression-free survival and overall response rate in comparison to PLD alone as a second-line treatment in ovarian cancer patients, providing basis for approval by the European Commission in 2009 CLINICAL TRIAL DESIGN  672 patient,

  35. Slide 35: Yondelis Japan STS: Positive Survival Trend and Superior PFS

    Yondelis® JAPAN STS: Positive Survival Trend and Superior PFS 100 90 Median 80 N 90% CI PFS Probability (%) 70 Trabectedin 37 5.6 4.2-7.5 60 BSC 36 0.9 0.9-1.0 50 40 30 HR= 0.07 (90% CI [0.03 , 0.14] ) 20 P value < 0.0001 10 0 0 3 6 9 12 15 Months 100 90 80 Median Probability (%) N 95% CI 70 OS 60 T

  36. Slide 36: PM1183: A Potent Oncology Compound

    PM1183: A Potent Oncology Compound PM1183: 2ND GENERATION TRABECTEDIN (YONDELIS®) WITH A PROVEN CLINICAL MECHANISM  Binds to minor groove and bends DNA, while freely interacting with proteins.  Forms inner strand cross links.  Marked effect on tumor microenvironment by inhibiting transcription of

  37. Slide 37: Phase IIb in Platinum-Resistant Ovarian Cancer

    PM1183: Phase IIb in Platinum-Resistant Ovarian Cancer  Schedule: 7 mg Flat Dose q3wk i.v. 1ST STAGE - COMPLETED  Go/No Go Criterion: at least 2 responses. 22 SUBJECTS MET PRIMARY ENDPOINT PM1183 7 MG FD Q3WK IV N= 30 PTS 2ND STAGE - COMPLETED RANDOMIZATION 1:1 CROSSOVER OPEN LABEL TOPOTECAN STAND

  38. Slide 38: Design of Metastatic Breast Cancer Phase IIb

    PM1183: Design of Metastatic Breast Cancer Phase IIb PM1183 SINGLE AGENT STAGE I ARM A ARM B MUT-BRCA1/2 (N=20) UNKNOWN STATUS (N=30) ≥ 4 pts ≥ 3 pts with ORR with ORR STAGE II + (N=33 PATIENTS) + (N=34 PATIENTS) PRIMARY ENDPOINT: OVERALL RESPONSE RATE (RECIST v1.1) Centers: Massachusetts General Ho

  39. Slide 39: Phase IIb PM1183/Gemcitabine Combo in NSCLC

    PM1183: Phase IIb PM1183/Gemcitabine Combo in NSCLC EGFR-NON MUTATED ADVANCED NSCLC (1 PRIOR LINE) N=120 STRATIFIED BY HISTOLOGY: SQUAMOUS VS. NON-SQUAMOUS PM1183 / GEM PM1183 ALONE DOCETAXEL (CTRL.) N=40 N=40 N=40  Primary endpoint: PFS at 4 months.  Secondary endpoints:  Safety  Response rate

  40. Slide 40: Aplidin: Chugai Agreement

    Aplidin®: Chugai Agreement -July 14, 2014 ZELTIA AND CHUGAI PHARMACEUTICAL HAVE ENTERED INTO A LICENSE AGREEMENT FOR Aplidin®  Chugai Pharma Marketing would promote PharmaMar’s Aplidin® for the treatment of multiple myeloma (MM) in eight European countries (France, Germany, the UK, Belgium, the Net

  41. Slide 41: For More Information: www.pharmamar.com

    FOR MORE INFORMATION: WWW.PHARMAMAR.COM

PharmaMar — Investor Presentation (November 2015) on 6ix